Indications
Therapeutic Asset Ratings
3,186 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
qh104 cell
Neoplastic Meningitis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
N/A
D
(30)
Red Blood Cells
Neonatal Anemia
Hospital Clinic of Barcelona
N/A
D
(30)
Red Blood Cells
Bronchopulmonary Dysplasia
Hospital Clinic of Barcelona
N/A
D
(30)
Red Blood Cells
Hereditary Persistence Of Fetal Hemoglobin
Hospital Clinic of Barcelona
N/A
D
(30)
Red Blood Cells
Retinopathy Of Prematurity
Hospital Clinic of Barcelona
N/A
D
(30)
Senl_B19 Autologous Car-T Treatment
B-Cell Acute Lymphoblastic Leukemia
Peking University People's Hospital
N/A
D
(30)
Senl_B19 Autologous Car-T Treatment
Acute Lymphoblastic Leukemia
Peking University People's Hospital
N/A
D
(30)
Senl_B19 Autologous Car-T Treatment
Adult Acute Lymphoblastic Leukemia
Peking University People's Hospital
N/A
D
(30)
Senl_B19 Autologous Car-T Treatment
Childhood Acute Lymphoblastic Leukemia
Peking University People's Hospital
N/A
D
(30)
Vgb-Ex01
Beta Thalassemia
Institute of Hematology & Blood Diseases Hospital, China
N/A
D
(30)
Vgb-Ex01
Beta-Thalassemia Major
Institute of Hematology & Blood Diseases Hospital, China
N/A
D
(30)
Γ-Globin Reactivated Autologous Hematopoietic Stem Cells
Beta-Thalassemia Major
Bioray Laboratories
N/A
D
(30)
Pd-L1 T-Hank
Cutaneous Neuroendocrine Carcinoma
ImmunityBio, Inc.
P2
D
(29)
cd22 car-t
Follicular Lymphoma
Stanford University
P1
D
(29)
Showing 2701 to 2725 of 3,186 assets
Previous
Page 109 of 128
Next